EFFECT OF THE CALCIUM-ANTAGONIST, NIFEDIPINE, ON ISCHEMIC RETINAL DYSFUNCTION

被引:52
|
作者
CROSSON, CE
WILLIS, JA
POTTER, DE
机构
[1] Houston Biotechnology, Incorportaed, The Woodlands, Texas
[2] Department of Ophthalmology, Texas Tech University, Lubbock, Texas
[3] Warehouse School of Medicine, Atlanta
来源
JOURNAL OF OCULAR PHARMACOLOGY | 1990年 / 6卷 / 04期
关键词
D O I
10.1089/jop.1990.6.293
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The therapeutic effectiveness of calcium channel antagonists (CCA) in hypertension and angina are well established. More recently, CCAs have also been demonstrated to ameliorate neurologic dysfunction that often accompanies ischemia associated with subarachnoid hemorrhage and stroke. We have hypothesized that retinal degeneration associated with ischemia may also result from the accumulation of calcium intracellularly, so-called "Ca++ overload". To test this hypothesis, a rat model of acute retinal ischemia, produced by direct occlusion of posterior ciliary and central retinal arteries, was developed. The extent of retinal dysfunction induced by ischemia was evaluated by electroretinograms (ERGs). Occlusion of the retinal arteries resulted in the disappearance ob both a- and b-waves during the occlusion period (30 minutes) in vehicle-treated rats. Total retinal ischemia did not produce any significant change in magnitude of ERG a-wave amplitude during three-hours of reperfusion. However, ERG b-waves amplitudes were significantly reduced by more than 60%. In rats, pretreatment with nifedipine (0.33 to 3.3 mg/kg, i.p.) 30 minutes prior to the occlusion of the retinal vessels produced a significant dose-dependent increase in the recovery of b-wave amplitude when compared to vehicle-treated rats. These data support the idea that "Ca++ overload", resulting from the deregulation of intracellular Ca++ homeostasis, is a primary factor involved in ischemic retinal degeneration and that CCAs can protect the retina from ischemic damage.
引用
收藏
页码:293 / 299
页数:7
相关论文
共 50 条
  • [21] SIMILARITIES AND DIFFERENCES IN THE ANTIHYPERTENSIVE EFFECT OF 2 CALCIUM-ANTAGONIST DRUGS, VERAPAMIL AND NIFEDIPINE
    AGABITIROSEI, E
    ROMANELLI, G
    MUIESAN, ML
    CASTELLANO, M
    BESCHI, M
    MUIESAN, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (02) : 225 - 225
  • [23] EARLY TREATMENT OF ISCHEMIC STROKE WITH A CALCIUM-ANTAGONIST
    ROSENBAUM, D
    ZABRAMSKI, J
    FREY, J
    YATSU, F
    MARLER, J
    SPETZLER, R
    GROTTA, J
    STROKE, 1991, 22 (04) : 437 - 441
  • [24] METABOLIC PROTECTION OF THE ISCHEMIC MYOCARDIUM BY A CALCIUM-ANTAGONIST
    MENDLER, N
    KIM, PG
    SEBENING, F
    EUROPEAN HEART JOURNAL, 1983, 4 : 82 - 83
  • [25] CALCIUM-ANTAGONIST NIFEDIPINE MODIFIES EXERCIS-INDUCED ASTHMA
    BARNES, PJ
    WILSON, NM
    BROWN, MJ
    IND, P
    THORAX, 1981, 36 (03) : 231 - 231
  • [26] INHIBITION OF EXERCISE-INDUCED ASTHMA BY A CALCIUM-ANTAGONIST, NIFEDIPINE
    CERRINA, J
    DENJEAN, A
    ALEXANDRE, G
    LOCKHART, A
    DUROUX, P
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1981, 123 (02): : 156 - 160
  • [27] INHIBITION OF EXERCISE-INDUCED ASTHMA BY A CALCIUM-ANTAGONIST (NIFEDIPINE)
    DENJEAN, A
    CERRINA, J
    GUENARD, H
    SIMONNEAU, G
    LOCKHART, A
    DUROUX, P
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1980, 10 (02) : 9 - 9
  • [28] EFFECT OF DILTIAZEM, A CALCIUM-ANTAGONIST, ON MYOCARDIAL PH IN ISCHEMIC CANINE HEART
    ICHIHARA, K
    ABIKO, Y
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1982, 222 (03): : 720 - 725
  • [29] THE EFFECT OF THE CALCIUM-ANTAGONIST NIFEDIPINE ON UTERINE CONTRACTILITY OF THE DOG BEFORE, DURING AND AFTER PARTURITION
    WURTH, Y
    VANDERWEYDEN, GC
    TAVERNE, MAM
    VANOORD, R
    TIJDSCHRIFT VOOR DIERGENEESKUNDE, 1986, 111 : S6 - S7
  • [30] INCREASED SURVIVAL LENGTH OF EXPERIMENTAL FLAP BY CALCIUM-ANTAGONIST NIFEDIPINE
    HIRA, M
    TAJIMA, S
    SANO, S
    ANNALS OF PLASTIC SURGERY, 1990, 24 (01) : 45 - 48